221 related articles for article (PubMed ID: 26676633)
1. Vγ9Vδ2 T cells and zoledronate mediate antitumor activity in an orthotopic mouse model of human chondrosarcoma.
Sun L; Li Y; Jiang Z; Zhang J; Li H; Li B; Ye Z
Tumour Biol; 2016 Jun; 37(6):7333-44. PubMed ID: 26676633
[TBL] [Abstract][Full Text] [Related]
2. Trastuzumab enhanced the cytotoxicity of Vγ9Vδ2 T cells against zoledronate-sensitized osteosarcoma cells.
Liu M; Sun LL; Li YJ; Li HY; Zhang J; Li BH; Ye ZM
Int Immunopharmacol; 2015 Sep; 28(1):160-7. PubMed ID: 26071219
[TBL] [Abstract][Full Text] [Related]
3. Adoptive transfer of ex vivo expanded Vγ9Vδ2 T cells in combination with zoledronic acid inhibits cancer growth and limits osteolysis in a murine model of osteolytic breast cancer.
Zysk A; DeNichilo MO; Panagopoulos V; Zinonos I; Liapis V; Hay S; Ingman W; Ponomarev V; Atkins G; Findlay D; Zannettino A; Evdokiou A
Cancer Lett; 2017 Feb; 386():141-150. PubMed ID: 27865798
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of the antitumor activity of human Vγ9Vδ2 T cells in combination with zoledronic acid in a preclinical model of neuroblastoma.
Di Carlo E; Bocca P; Emionite L; Cilli M; Cipollone G; Morandi F; Raffaghello L; Pistoia V; Prigione I
Mol Ther; 2013 May; 21(5):1034-43. PubMed ID: 23481325
[TBL] [Abstract][Full Text] [Related]
5. Zoledronic acid and interleukin-2 treatment improves immunocompetence in HIV-infected persons by activating Vgamma9Vdelta2 T cells.
Poccia F; Gioia C; Martini F; Sacchi A; Piacentini P; Tempestilli M; Agrati C; Amendola A; Abdeddaim A; Vlassi C; Malkovsky M; D'Offizi G
AIDS; 2009 Mar; 23(5):555-65. PubMed ID: 19238075
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxic effects of gammadelta T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy.
Sato K; Kimura S; Segawa H; Yokota A; Matsumoto S; Kuroda J; Nogawa M; Yuasa T; Kiyono Y; Wada H; Maekawa T
Int J Cancer; 2005 Aug; 116(1):94-9. PubMed ID: 15756684
[TBL] [Abstract][Full Text] [Related]
7. Aminobisphosphonates Synergize with Human Cytomegalovirus To Activate the Antiviral Activity of Vγ9Vδ2 Cells.
Daguzan C; Moulin M; Kulyk-Barbier H; Davrinche C; Peyrottes S; Champagne E
J Immunol; 2016 Mar; 196(5):2219-29. PubMed ID: 26819204
[TBL] [Abstract][Full Text] [Related]
8. In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients.
Meraviglia S; Eberl M; Vermijlen D; Todaro M; Buccheri S; Cicero G; La Mendola C; Guggino G; D'Asaro M; Orlando V; Scarpa F; Roberts A; Caccamo N; Stassi G; Dieli F; Hayday AC
Clin Exp Immunol; 2010 Aug; 161(2):290-7. PubMed ID: 20491785
[TBL] [Abstract][Full Text] [Related]
9. High phosphoantigen levels in bisphosphonate-treated human breast tumors promote Vgamma9Vdelta2 T-cell chemotaxis and cytotoxicity in vivo.
Benzaïd I; Mönkkönen H; Stresing V; Bonnelye E; Green J; Mönkkönen J; Touraine JL; Clézardin P
Cancer Res; 2011 Jul; 71(13):4562-72. PubMed ID: 21646473
[TBL] [Abstract][Full Text] [Related]
10. Repeated systemic administrations of both aminobisphosphonates and human Vγ9Vδ2 T cells efficiently control tumor development in vivo.
Santolaria T; Robard M; Léger A; Catros V; Bonneville M; Scotet E
J Immunol; 2013 Aug; 191(4):1993-2000. PubMed ID: 23836057
[TBL] [Abstract][Full Text] [Related]
11. Ex vivo characterization of γδ T-cell repertoire in patients after adoptive transfer of Vγ9Vδ2 T cells expressing the interleukin-2 receptor β-chain and the common γ-chain.
Izumi T; Kondo M; Takahashi T; Fujieda N; Kondo A; Tamura N; Murakawa T; Nakajima J; Matsushita H; Kakimi K
Cytotherapy; 2013 Apr; 15(4):481-91. PubMed ID: 23391461
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy and zoledronate sensitize solid tumour cells to Vgamma9Vdelta2 T cell cytotoxicity.
Mattarollo SR; Kenna T; Nieda M; Nicol AJ
Cancer Immunol Immunother; 2007 Aug; 56(8):1285-97. PubMed ID: 17265022
[TBL] [Abstract][Full Text] [Related]
13. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy.
Kondo M; Sakuta K; Noguchi A; Ariyoshi N; Sato K; Sato S; Sato K; Hosoi A; Nakajima J; Yoshida Y; Shiraishi K; Nakagawa K; Kakimi K
Cytotherapy; 2008; 10(8):842-56. PubMed ID: 19016372
[TBL] [Abstract][Full Text] [Related]
14. Aminobisphosphonate-pretreated dendritic cells trigger successful Vgamma9Vdelta2 T cell amplification for immunotherapy in advanced cancer patients.
Cabillic F; Toutirais O; Lavoué V; de La Pintière CT; Daniel P; Rioux-Leclerc N; Turlin B; Mönkkönen H; Mönkkönen J; Boudjema K; Catros V; Bouet-Toussaint F
Cancer Immunol Immunother; 2010 Nov; 59(11):1611-9. PubMed ID: 20582413
[TBL] [Abstract][Full Text] [Related]
15. [Effect of zoledronate on the cytotoxicity of γδ T cells from PBMCs of osteosarcoma patients against osteosarcoma].
Li Z; Tang J; Sun L; Ye Z
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 Jan; 29(1):6-9. PubMed ID: 23294710
[TBL] [Abstract][Full Text] [Related]
16. Hepatocellular carcinoma cell sensitivity to Vγ9Vδ2 T lymphocyte-mediated killing is increased by zoledronate.
Sugai S; Yoshikawa T; Iwama T; Tsuchiya N; Ueda N; Fujinami N; Shimomura M; Zhang R; Kaneko S; Uemura Y; Nakatsura T
Int J Oncol; 2016 May; 48(5):1794-804. PubMed ID: 26936487
[TBL] [Abstract][Full Text] [Related]
17. Sensitization of human osteosarcoma cells to Vγ9Vδ2 T-cell-mediated cytotoxicity by zoledronate.
Li Z; Peng H; Xu Q; Ye Z
J Orthop Res; 2012 May; 30(5):824-30. PubMed ID: 22025284
[TBL] [Abstract][Full Text] [Related]
18. Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice.
Lu S; Zhang J; Zhou Z; Liao ML; He WZ; Zhou XY; Li ZM; Xiang JQ; Wang JJ; Chen HQ
Oncol Rep; 2008 Sep; 20(3):581-7. PubMed ID: 18695909
[TBL] [Abstract][Full Text] [Related]
19. Potent antitumor activity of zoledronic acid-induced Vγ9Vδ2 T cells against primary effusion lymphoma.
Goto H; Matsuda K; Srikoon P; Kariya R; Hattori S; Taura M; Katano H; Okada S
Cancer Lett; 2013 May; 331(2):174-82. PubMed ID: 23321500
[TBL] [Abstract][Full Text] [Related]
20. Intraperitoneal injection of in vitro expanded Vγ9Vδ2 T cells together with zoledronate for the treatment of malignant ascites due to gastric cancer.
Wada I; Matsushita H; Noji S; Mori K; Yamashita H; Nomura S; Shimizu N; Seto Y; Kakimi K
Cancer Med; 2014 Apr; 3(2):362-75. PubMed ID: 24515916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]